A Single Injection Is Replacing Steroids for Severe Asthma and COPD Attacks

For over 50 years, the emergency protocol for a severe asthma or chronic obstructive pulmonary disease (COPD) attack has remained stubbornly unchanged. When a patient arrives at the hospital gasping for air, the immediate response is a heavy dose of systemic oral corticosteroids.[3]

While these steroids—typically prednisolone—are highly effective at rapidly suppressing the immune system to open the airways, they act as a blunt instrument. They flood the entire body, bringing a cascade of severe side effects that actively undermine a patient's long-term wellness.

Patients frequently endure extreme mood swings, insomnia, rapid weight gain, and dangerous spikes in blood sugar. Over time, repeated courses of oral steroids degrade bone density, leading to osteoporosis, and significantly increase the risk of cataracts and cardiovascular disease.[4]

Now, a landmark clinical trial has demonstrated that this half-century-old standard of care may finally be obsolete. Researchers have proven that a single, targeted injection of a biologic drug called benralizumab can halt acute respiratory attacks more effectively than a five-day course of steroids.[1]

The findings, published in The Lancet Respiratory Medicine, stem from the ABRA (Acute exacerbations treated with BenRAlizumab) trial, a rigorous phase 2 study conducted across multiple hospitals in the United Kingdom.[1][2]

To understand why this is a paradigm shift, it is necessary to look at the underlying biology of a respiratory attack. Historically, doctors treated "asthma" or "COPD" as monolithic diseases. Today, pulmonologists recognize that these conditions are driven by distinct inflammatory "endotypes."

In roughly 50 percent of asthma attacks and 30 percent of COPD flare-ups, the crisis is triggered by an overproduction of eosinophils—a specific type of white blood cell. When the body detects an allergen or irritant, it floods the lungs with eosinophils, causing severe swelling and mucus production that blocks the airways.[1][4]

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody designed specifically to hunt down and eliminate these rogue cells. It binds to the interleukin-5 (IL-5) receptor alpha on the surface of eosinophils.[4]

Once attached, the biologic acts like a homing beacon, signaling the body's natural killer cells to destroy the eosinophils through a process called apoptosis, or programmed cell death. Within 24 hours, the eosinophil count in the blood drops to near zero, extinguishing the source of the lung inflammation.[4][5]

In the ABRA trial, 158 patients arriving at the hospital with acute eosinophilic exacerbations were randomly assigned to receive either standard oral prednisolone, a single benralizumab injection, or a combination of both.[1][2]

The results were striking. After 90 days, patients who received only the standard steroid treatment experienced a 74 percent rate of treatment failure—meaning they required further medical intervention, additional steroids, or hospital readmission.[1]

In stark contrast, the treatment failure rate for those receiving benralizumab plummeted to just 45 percent. The biologic effectively quadrupled the likelihood of a sustained recovery compared to the 50-year-old standard of care.[1][3]

Furthermore, patients in the benralizumab group reported significantly better symptom relief at the 28-day mark. They experienced less coughing, wheezing, and breathlessness, allowing them to return to their normal daily routines and exercise regimens much faster.[1]

Crucially, the biologic completely bypassed the systemic collateral damage of steroids. The trial noted that adverse events like hyperglycemia and acute sinus infections occurred exclusively in the prednisolone group. The benralizumab injection was exceptionally well tolerated.[1]

This precision-medicine approach represents a massive victory for patient wellness. By neutralizing only the specific cells causing the attack, benralizumab leaves the rest of the immune system intact and spares the endocrine and metabolic systems from steroid-induced chaos.[5]

However, implementing this breakthrough in everyday emergency rooms will require a logistical shift. Because benralizumab only works for eosinophilic exacerbations, doctors cannot simply administer it to everyone who walks through the door wheezing.

Hospitals will need to perform rapid blood tests—specifically a complete blood count with a differential—to confirm that a patient's eosinophil levels are elevated (typically above 300 cells per microliter) before giving the injection.[1][2]

While this adds a step to the triage process, rapid diagnostic testing is already becoming standard in modern emergency departments. The upfront cost of the biologic and the blood test is heavily offset by the dramatic reduction in hospital readmissions and long-term steroid complications.[3][5]

As researchers prepare for larger phase 3 trials to secure formal regulatory approval for this acute use case, the respiratory medicine community is already celebrating the data. For millions of patients living with severe asthma and COPD, the terror of an attack may soon be decoupled from the dread of the steroid prescription that follows.[5]